PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 12, 2026Pediatric Obesity

Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity‐Related Genes

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMostafa SalamaDHDoha HassanRSRebecca Signer

Discussion

Loading...

Member takes

Overview

Retrospective chart review shows semaglutide reduces BMI and improves cardiometabolic markers in adolescents with genetic obesity variants, suggesting beneficial effects.

Key Points

  • This research aims to assess the effects of semaglutide on BMI and cardiometabolic health in adolescents with genetic variants linked to obesity.
  • Retrospective chart review of adolescents with severe obesity treated with semaglutide.
  • Participants underwent multigene panel testing for obesity-related genetic variants.
  • Assessment of BMI and various cardiometabolic markers before and after treatment.
  • All groups exhibited reductions in BMI with no significant differences between them.
  • Adolescents with known risk variants showed a significant decrease in BMI % of the 95th percentile by −17.
  • Notable improvements in non-HDL cholesterol, total cholesterol, and HbA1c were found in the high-risk group.

Cite This Study

Salama et al. (2026) studied this question.

synapsesocial.com/papers/698d6e055be6419ac0d536c3https://doi.org/10.1111/ijpo.70091
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study2025 · 6 citations
  2. 2Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study2025
  3. 3Semaglutide <scp>2.4 mg</scp> Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( <scp>SMILE</scp> )2026
  4. 4Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report2024 · 4 citations
  5. 5Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity2026